January 7, 2019 / 2:49 PM / 6 months ago

U.S. Supreme Court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 (Reuters) - The U.S. Supreme Court on Monday declined to take up Amgen Inc's bid to reinstate a jury verdict it won against rivals Regeneron Pharmaceuticals Inc and Sanofi SA in patent dispute over cholesterol medication.

The justices turned away Amgen's appeal of a 2017 decision by a lower court to set aside a jury's verdict that two Amgen patents were valid and nullify a ban on sales of Regeneron and Sanofi SA's cholesterol-lowering drug Praluent. Amgen had argued that the U.S. Court of Appeals for the Federal Circuit misunderstood the statutory requirements for patenting an invention.

Reporting by Jan Wolfe and Lawrence Hurley; Editing by Will Dunham

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below